Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells

Chimeric antigen receptor (CAR) T-cell immunotherapy still faces many challenges in the treatment of solid tumors, one of which is T-cell dysfunction or exhaustion. Immunomodulator lenalidomide may improve CAR T-cell function. In this study, the effects of lenalidomide on CAR T-cell functions (cytot...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhixiong, Zhou, Guomin, Risu, Na, Fu, Jiayu, Zou, Yan, Tang, Jiaxing, Li, Long, Liu, Hui, Liu, Qian, Zhu, Xuekai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Cancer Pharmacogenomics and Target Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784582/
https://www.ncbi.nlm.nih.gov/pubmed/32967454
http://dx.doi.org/10.1177/0963689720920825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784582/
https://www.ncbi.nlm.nih.gov/pubmed/32967454
http://dx.doi.org/10.1177/0963689720920825

Ejemplares similares